Skip to content
Sign up free
News

FDA approves ella, a new emergency contraception pill

By Adrienne Verrilli

2-minute read

Late Friday afternoon, the U.S Food and Drug Administration (FDA) announced approval of a new option of emergency contraception known as ella.  Already available to women in 22 countries, ella provides women with the option to prevent pregnancy up to 120 hours (or 5 days) after unprotected sex.

A federal advisory panel recommended ella’s approval in an 11-0 vote back in June. Emergency contraception currently available to American women – Plan B - prevents pregnancy up to 72 hours after unprotected sex. Unlike Plan B, however, which is available without a prescription for women 18-years old and older, ella will require a prescription from a physician. It is expected to be available at the end of 2010.

In a Washington Post article, Kristen Moore, president of the Reproductive Health Technology Project succinctly summarized the FDA’s move:

"Women's health advocates appreciate that the review process for ella was consistent with standard FDA procedure and based on scientific evidence, not politics. Approval of ella is further evidence that the FDA is committed to restoring scientific integrity in its decisions."

What Ms. Moore was alluding to was the Bush Administration's overruling of FDA scientists, delay in the decision to make Plan B available to women over the counter, and barring of the availability to women under 18 unless they had a prescription.

Upon ella’s approval, the anti-abortion movement quickly denounced the decision charging that ella is the same as a medical abortion. "Ella is an abortion drug," said Wendy Wright, President of Concerned Women for America. "It operates the same way as RU-486, the abortion drug. Many women may be comfortable taking a contraceptive but would object to taking an abortion drug."

The FDA claims that ella prevents pregnancy by preventing or inhibiting ovulation. It will not work if a woman is already pregnant. The data also shows ella to be more effective at delaying ovulation than other methods of emergency contraception during the time when women have the highest chance of getting pregnant, may experience contraceptive failure, and are most likely to be having sex. Mifepristone (a medical abortion), on the other hand, dislodges an implanted egg from the uterus up to 49 days into gestation.

Approximately six million pregnancies occur in the U.S. each year, half of which – nearly 3 million – are unintended. Given this staggering number of unintended pregnancies, I believe the news of ella’s approval is welcome news. When women spend the majority of their reproductive years avoiding pregnancy, it would seem reasonable to continue to pursue and bring to the market every available option so that all women can plan when and whether to become a mother.

*  Editor's note:  Readers should also consult the attached PDF release from the FDA detailing warnings associated with ella.

Tags: News

Adhere to the IVN etiquette

By posting a comment, you agree to adhere to our etiquette rules: No partisan attacks, no personal attacks, substantiate your sources, no self-promotion.

Get IVN’s Free Weekly Newsletter:Get IVN’s Free Newsletter

Get IVN’s Free Weekly Newsletter:Get IVN’s Free Newsletter

Nonpartisan Issues. Diverse Perspectives.

Check your inbox and click the link to confirm.

Republish this article

Republishing guidelines

Republish IVN articles for free. Independent Voter News articles may be republished online or in print under a Creative Commons BY-NC-ND 4.0 license, on these terms:

  1. Credit the author and IVN. Keep the byline ("By Author Name, Independent Voter News") and the attribution note at the end, which links to the original.
  2. Keep the meaning. You may update time and place references and apply your house style. You may trim for length, as long as the cuts don't change the meaning or misrepresent the author. Keep the headline. Mark any additions as your own (for example "Additional reporting by ...").
  3. Translations are welcome. Translate faithfully, add "Translated from English by [your outlet]", and tell us at editor@ivn.us.
  4. Keep the links, including the link to the original article.
  5. Keep the tracking image. The HTML includes a 1-pixel image that counts readers on your page. It collects no personal information.
  6. Photos and illustrations. Images credited to IVN may be used with this article only. Images credited to others (AP, Getty, Unsplash, Wikimedia and so on) stay under their owners' terms. Secure the rights or switch "Include images" off.
  7. Don't sell it. You can't sell our articles or sell ads specifically against them. Your normal site advertising is fine.
  8. No implied endorsement. Don't suggest that IVN or the author endorses you, your candidates or your causes, or that donations to you support IVN.
  9. Keep labels. Opinion or analysis pieces keep that label.
  10. Point search engines to the original. Where your CMS allows, set the canonical URL to the original IVN article.
  11. No bulk or automated republishing, and don't submit our articles to aggregators (Apple News, Google News, MSN) as your own.
  12. Corrections and removals. Update your copy when we correct it, and remove it promptly if we ask. We'll contact you at the email you give us.
  13. Questions or print republication: editor@ivn.us.

IVN staff: fill in who you're inviting above, then create the invite.

Preparing the article

FDA approves ella, a new emergency contraception pill

Choose a format
  • HTML
  • Email HTML
  • Markdown
  • Formatted (.docx)
  • Plain text
  • WordPress blocks
  • PDF
Choose a platform

Photos credited to others need their owners' permission.

To for

Republishing somewhere else? Questions? editor@ivn.us